Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 13Paraganglioma 5Carcinoid Tumor 5Pheochromocytoma 4Neuroblastoma 4von Hippel-Lindau Disease 3Multiple Endocrine Neoplasia Type 1 2Medulloblastoma 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Neuroendocrine 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Multiple Endocrine Neoplasia 1Metastatic Neuroendocrine Prostate Cancer 1Meningioma 1Kidney Neoplasms 1Hypoglycemia 1Hypertension 1Hyperparathyroidism 1Hypercalcemia 1Head and Neck Neoplasms 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Capecitabine 6Temozolomide 5Octreotide 4Everolimus 4Leucovorin 3vatalanib 2pentetreotide 2Trastuzumab 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Fluorouracil 2Cisplatin 2Bortezomib 2Biological Therapy 2Bevacizumab 2veliparib 1tipifarnib 1romidepsin 1regorafenib 1pazopanib 1motesanib diphosphate 1gallium Ga 68 dotatate 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1aflibercept 1Thalidomide 1Streptozocin 1Specimen Handling 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Somatostatinoma × gallium Ga 68 dotatate × Endocrine × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡